Do analysts recommend OSRH or BTCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, OSRH or BTCY?

Biotricity has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OSR $2.91M 5.11 -$27.06M -$0.33 N/A Biotricity $12.06M 0.26 -$14.09M -$0.16 N/A

Is OSRH or BTCY more profitable?

Biotricity has a net margin of -80.42% compared to OSR's net margin of -363.26%. Biotricity's return on equity of 0.00% beat OSR's return on equity. Company Net Margins Return on Equity Return on Assets OSR -363.26% -7.24% -5.41% Biotricity -80.42% N/A -188.47%

Do analysts prefer SURG or BTCY?

SurgePays currently has a consensus price target of $3.50, suggesting a potential upside of 693.65%. Given SurgePays' stronger consensus rating and higher probable upside, equities analysts plainly believe SurgePays is more favorable than Biotricity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is SURG or BTCY more profitable?

SurgePays has a net margin of -64.91% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat SurgePays' return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% -967.32% -310.16% Biotricity -80.42% N/A -188.47%

Do analysts rate BTCY or ALUR?

Allurion Technologies has a consensus target price of $3.00, suggesting a potential upside of 300.00%. Given Allurion Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Allurion Technologies is more favorable than Biotricity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Allurion Technologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BTCY or ALUR more profitable?

Biotricity has a net margin of -80.42% compared to Allurion Technologies' net margin of -199.96%. Company Net Margins Return on Equity Return on Assets Biotricity -80.42% N/A -188.47% Allurion Technologies -199.96% N/A -77.13%

Do analysts rate ICU or BTCY?

SeaStar Medical currently has a consensus price target of $8.00, indicating a potential upside of 205.23%. Given SeaStar Medical's stronger consensus rating and higher possible upside, research analysts clearly believe SeaStar Medical is more favorable than Biotricity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SeaStar Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend BTCY or ICCM?

IceCure Medical has a consensus price target of $62.70, indicating a potential upside of 2,344.44%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts clearly believe IceCure Medical is more favorable than Biotricity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 IceCure Medical 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is BTCY or ICCM more profitable?

Biotricity has a net margin of -80.42% compared to IceCure Medical's net margin of -441.60%. Biotricity's return on equity of 0.00% beat IceCure Medical's return on equity. Company Net Margins Return on Equity Return on Assets Biotricity -80.42% N/A -188.47% IceCure Medical -441.60% -211.73% -119.13%

Biotricity (BTCY) Competitors

$0.11 0.00 (0.00%)

As of 11:47 AM Eastern

Compare

BTCY vs. OSRH, SURG, ALUR, ICU, and ICCM

Should you buy Biotricity stock or one of its competitors? MarketBeat compares Biotricity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biotricity include OSR (OSRH), SurgePays (SURG), Allurion Technologies (ALUR), SeaStar Medical (ICU), and IceCure Medical (ICCM). These companies are all part of the "medical equipment" industry.

How does Biotricity compare to OSR?

OSR (NASDAQ:OSRH) and Biotricity (NASDAQ:BTCY) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

In the previous week, OSR had 2 more articles in the media than Biotricity. MarketBeat recorded 2 mentions for OSR and 0 mentions for Biotricity. OSR's average media sentiment score of 0.47 beat Biotricity's score of 0.00 indicating that OSR is being referred to more favorably in the media.

Company	Overall Sentiment
OSR	Neutral
Biotricity	Neutral

Biotricity has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$2.91M	5.11	-$27.06M	-$0.33	N/A
Biotricity	$12.06M	0.26	-$14.09M	-$0.16	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

OSR has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Biotricity has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Biotricity has a net margin of -80.42% compared to OSR's net margin of -363.26%. Biotricity's return on equity of 0.00% beat OSR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-363.26%	-7.24%	-5.41%
Biotricity	-80.42%	N/A	-188.47%

55.3% of OSR shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 36.8% of OSR shares are owned by insiders. Comparatively, 10.1% of Biotricity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

OSR and Biotricity tied by winning 7 of the 14 factors compared between the two stocks.

How does Biotricity compare to SurgePays?

SurgePays (NASDAQ:SURG) and Biotricity (NASDAQ:BTCY) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

SurgePays has a net margin of -64.91% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	-967.32%	-310.16%
Biotricity	-80.42%	N/A	-188.47%

6.9% of SurgePays shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 29.1% of SurgePays shares are held by insiders. Comparatively, 10.1% of Biotricity shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

SurgePays currently has a consensus price target of $3.50, suggesting a potential upside of 693.65%. Given SurgePays' stronger consensus rating and higher probable upside, equities analysts plainly believe SurgePays is more favorable than Biotricity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, SurgePays had 8 more articles in the media than Biotricity. MarketBeat recorded 8 mentions for SurgePays and 0 mentions for Biotricity. SurgePays' average media sentiment score of 0.97 beat Biotricity's score of 0.00 indicating that SurgePays is being referred to more favorably in the media.

Company	Overall Sentiment
SurgePays	Positive
Biotricity	Neutral

SurgePays has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Biotricity has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Biotricity has lower revenue, but higher earnings than SurgePays. Biotricity is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.19	-$36.07M	-$1.94	N/A
Biotricity	$12.06M	0.26	-$14.09M	-$0.16	N/A

Summary

SurgePays beats Biotricity on 9 of the 16 factors compared between the two stocks.

How does Biotricity compare to Allurion Technologies?

Biotricity (NASDAQ:BTCY) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Biotricity has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.13, indicating that its share price is 113% less volatile than the broader market.

Allurion Technologies has a consensus target price of $3.00, suggesting a potential upside of 300.00%. Given Allurion Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Allurion Technologies is more favorable than Biotricity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Allurion Technologies has higher revenue and earnings than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.26	-$14.09M	-$0.16	N/A
Allurion Technologies	$17.21M	0.65	-$7.20M	-$2.03	N/A

Biotricity has a net margin of -80.42% compared to Allurion Technologies' net margin of -199.96%.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
Allurion Technologies	-199.96%	N/A	-77.13%

In the previous week, Biotricity's average media sentiment score of 0.00 equaled Allurion Technologies'average media sentiment score.

Company	Overall Sentiment
Biotricity	Neutral
Allurion Technologies	Neutral

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 10.1% of Biotricity shares are owned by company insiders. Comparatively, 8.1% of Allurion Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Allurion Technologies beats Biotricity on 9 of the 13 factors compared between the two stocks.

How does Biotricity compare to SeaStar Medical?

SeaStar Medical (NASDAQ:ICU) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

SeaStar Medical has higher earnings, but lower revenue than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than SeaStar Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SeaStar Medical	$1.23M	8.52	-$12.15M	-$4.80	N/A
Biotricity	$12.06M	0.26	-$14.09M	-$0.16	N/A

SeaStar Medical has a beta of -1.05, suggesting that its share price is 205% less volatile than the broader market. Comparatively, Biotricity has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

SeaStar Medical currently has a consensus price target of $8.00, indicating a potential upside of 205.23%. Given SeaStar Medical's stronger consensus rating and higher possible upside, research analysts clearly believe SeaStar Medical is more favorable than Biotricity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, SeaStar Medical had 3 more articles in the media than Biotricity. MarketBeat recorded 3 mentions for SeaStar Medical and 0 mentions for Biotricity. SeaStar Medical's average media sentiment score of 0.93 beat Biotricity's score of 0.00 indicating that SeaStar Medical is being referred to more favorably in the media.

Company	Overall Sentiment
SeaStar Medical	Positive
Biotricity	Neutral

Biotricity has a net margin of -80.42% compared to SeaStar Medical's net margin of -828.62%. Biotricity's return on equity of 0.00% beat SeaStar Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SeaStar Medical	-828.62%	-146.29%	-96.48%
Biotricity	-80.42%	N/A	-188.47%

1.7% of SeaStar Medical shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 0.7% of SeaStar Medical shares are held by insiders. Comparatively, 10.1% of Biotricity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

SeaStar Medical and Biotricity tied by winning 8 of the 16 factors compared between the two stocks.

How does Biotricity compare to IceCure Medical?

Biotricity (NASDAQ:BTCY) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

In the previous week, IceCure Medical had 2 more articles in the media than Biotricity. MarketBeat recorded 2 mentions for IceCure Medical and 0 mentions for Biotricity. IceCure Medical's average media sentiment score of 0.96 beat Biotricity's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Biotricity	Neutral
IceCure Medical	Positive

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 10.1% of Biotricity shares are owned by insiders. Comparatively, 2.4% of IceCure Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Biotricity has higher revenue and earnings than IceCure Medical. Biotricity is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.26	-$14.09M	-$0.16	N/A
IceCure Medical	$3.38M	2.13	-$15.06M	-$7.21	N/A

Biotricity has a net margin of -80.42% compared to IceCure Medical's net margin of -441.60%. Biotricity's return on equity of 0.00% beat IceCure Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
IceCure Medical	-441.60%	-211.73%	-119.13%

Biotricity has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

IceCure Medical has a consensus price target of $62.70, indicating a potential upside of 2,344.44%. Given IceCure Medical's stronger consensus rating and higher possible upside, analysts clearly believe IceCure Medical is more favorable than Biotricity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
IceCure Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Biotricity beats IceCure Medical on 9 of the 16 factors compared between the two stocks.

Get Biotricity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTCY vs. The Competition

Export

Metric	Biotricity	Surgical & medical instruments Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.15M	$39.43M	$6.48B	$11.73B
Dividend Yield	N/A	1.08%	2.67%	5.62%
P/E Ratio	-0.10	15.81	24.68	23.79
Price / Sales	0.26	25.67	473.06	85.09
Price / Cash	N/A	18.87	43.05	54.72
Price / Book	-0.08	14.54	10.44	6.73
Net Income	-$14.09M	-$20.60M	$3.56B	$337.26M
7 Day Performance	-14.86%	-1.58%	-2.64%	-2.07%
1 Month Performance	-54.92%	-9.41%	0.02%	0.68%
1 Year Performance	-77.99%	-8.59%	21.12%	24.60%

Biotricity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTCY Biotricity	N/A	$0.11 flat	N/A	-78.0%	$3.15M	$12.06M	N/A	40
OSRH OSR	1.0551 of 5 stars	$0.42 -1.1%	N/A	-75.0%	$14.77M	$2.91M	N/A	N/A
SURG SurgePays	3.7116 of 5 stars	$0.54 +2.9%	$5.00 +824.2%	-83.5%	$13.20M	$56.96M	N/A	40	Analyst Forecast
ALUR Allurion Technologies	1.324 of 5 stars	$0.88 +2.9%	$3.00 +241.1%	-71.1%	$13.19M	$17.21M	N/A	501	Gap Down
ICU SeaStar Medical	3.4889 of 5 stars	$3.13 -4.6%	$8.00 +155.6%	-79.0%	$13.11M	$1.23M	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTCY) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biotricity (BTCY) Competitors

BTCY vs. OSRH, SURG, ALUR, ICU, and ICCM

How does Biotricity compare to OSR?

Summary

How does Biotricity compare to SurgePays?

Summary

How does Biotricity compare to Allurion Technologies?

Summary

How does Biotricity compare to SeaStar Medical?

Summary

How does Biotricity compare to IceCure Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTCY vs. The Competition

Biotricity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biotricity (BTCY) Competitors

BTCY vs. OSRH, SURG, ALUR, ICU, and ICCM

How does Biotricity compare to OSR?

Does the media favor OSRH or BTCY?

Which has stronger earnings & valuation, OSRH or BTCY?

Do analysts recommend OSRH or BTCY?

Which has more volatility and risk, OSRH or BTCY?

Is OSRH or BTCY more profitable?

Do insiders & institutionals hold more shares of OSRH or BTCY?

Summary

How does Biotricity compare to SurgePays?

Is SURG or BTCY more profitable?

Do institutionals & insiders have more ownership in SURG or BTCY?

Do analysts prefer SURG or BTCY?

Does the media favor SURG or BTCY?

Which has more volatility & risk, SURG or BTCY?

Which has preferable earnings & valuation, SURG or BTCY?

Summary

How does Biotricity compare to Allurion Technologies?

Which has more volatility & risk, BTCY or ALUR?

Do analysts rate BTCY or ALUR?

Which has better earnings and valuation, BTCY or ALUR?

Is BTCY or ALUR more profitable?

Does the media prefer BTCY or ALUR?

Do insiders & institutionals have more ownership in BTCY or ALUR?

Summary

How does Biotricity compare to SeaStar Medical?

Which has better valuation and earnings, ICU or BTCY?

Which has more risk and volatility, ICU or BTCY?

Do analysts rate ICU or BTCY?

Does the media prefer ICU or BTCY?

Is ICU or BTCY more profitable?

Do insiders & institutionals believe in ICU or BTCY?

Summary

How does Biotricity compare to IceCure Medical?

Does the media favor BTCY or ICCM?

Do insiders & institutionals believe in BTCY or ICCM?

Which has preferable valuation & earnings, BTCY or ICCM?

Is BTCY or ICCM more profitable?

Which has more volatility & risk, BTCY or ICCM?

Do analysts recommend BTCY or ICCM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTCY vs. The Competition

Biotricity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools